Solvency ratios also known as long-term debt ratios measure a company ability to meet long-term obligations.
Paying user area
Try for free
Abbott Laboratories pages available for free this week:
- Common-Size Balance Sheet: Assets
- Analysis of Geographic Areas
- Common Stock Valuation Ratios
- Enterprise Value (EV)
- Enterprise Value to FCFF (EV/FCFF)
- Capital Asset Pricing Model (CAPM)
- Dividend Discount Model (DDM)
- Selected Financial Data since 2005
- Price to Operating Profit (P/OP) since 2005
- Analysis of Revenues
The data is hidden behind: . Unhide it.
Get full access to the entire website from $10.42/mo, or
get 1-month access to Abbott Laboratories for $24.99.
This is a one-time payment. There is no automatic renewal.
We accept:
Solvency Ratios (Summary)
Based on: 10-K (reporting date: 2025-12-31), 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31).
The solvency position, as indicated by the presented metrics, demonstrates a consistent strengthening over the five-year period from 2021 to 2025. A general trend of decreasing leverage and improving coverage ratios is observed. The inclusion of operating lease liabilities consistently results in slightly higher leverage ratios compared to those calculated excluding these liabilities, but the trend remains consistent across both sets of metrics.
- Debt Ratios
- Debt to equity, debt to capital, and debt to assets all exhibit declining trends. Debt to equity decreased from 0.50 in 2021 to 0.25 in 2025. Similarly, debt to capital decreased from 0.34 to 0.20 over the same period, and debt to assets decreased from 0.24 to 0.15. These declines suggest a decreasing reliance on debt financing relative to equity, capital, and total assets.
- Leverage Ratio
- Financial leverage decreased steadily from 2.10 in 2021 to 1.66 in 2025. This indicates a reduction in the proportion of assets financed by debt, further supporting the observation of a strengthening solvency position.
- Coverage Ratios
- Interest coverage experienced a decrease from 16.41 in 2021 to 11.46 in 2023, but then increased to 18.17 in 2025. This suggests an initial period of potentially increased interest expense or decreased earnings before interest and taxes, followed by a substantial improvement in the ability to cover interest obligations. Fixed charge coverage followed a similar pattern, declining to 7.71 in 2023 before rising to 10.58 in 2025, indicating an improved capacity to meet all fixed financing obligations.
Overall, the observed trends suggest a conservative and improving financial structure. The company appears to be reducing its debt burden and enhancing its ability to meet its financial obligations, as evidenced by the declining debt ratios and increasing coverage ratios, particularly in the later years of the period.
Debt Ratios
Coverage Ratios
Debt to Equity
| Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | ||
|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | ||||||
| Current portion of long-term debt | ||||||
| Long-term debt, excluding current portion | ||||||
| Total debt | ||||||
| Total Abbott shareholders’ investment | ||||||
| Solvency Ratio | ||||||
| Debt to equity1 | ||||||
| Benchmarks | ||||||
| Debt to Equity, Competitors2 | ||||||
| Elevance Health Inc. | ||||||
| Intuitive Surgical Inc. | ||||||
| Medtronic PLC | ||||||
| UnitedHealth Group Inc. | ||||||
| Debt to Equity, Sector | ||||||
| Health Care Equipment & Services | ||||||
| Debt to Equity, Industry | ||||||
| Health Care | ||||||
Based on: 10-K (reporting date: 2025-12-31), 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31).
1 2025 Calculation
Debt to equity = Total debt ÷ Total Abbott shareholders’ investment
= ÷ =
2 Click competitor name to see calculations.
The debt to equity ratio demonstrates a consistent downward trend over the five-year period. This indicates a decreasing reliance on debt financing relative to equity financing.
- Debt to Equity Ratio Trend
- In 2021, the debt to equity ratio was 0.50. This signifies that for every dollar of equity, the company held 50 cents of debt.
- By 2022, the ratio had decreased to 0.46, suggesting a modest reduction in financial leverage.
- The decline continued in 2023, with the ratio falling to 0.38, indicating a further strengthening of the company’s equity position relative to its debt.
- A more pronounced decrease was observed in 2024, as the ratio reached 0.30. This represents a substantial improvement in the company’s solvency.
- The trend culminated in 2025, with the debt to equity ratio reaching 0.25. This indicates that for every dollar of equity, the company held only 25 cents of debt, representing the lowest level of leverage within the observed period.
Concurrently with the decreasing debt to equity ratio, total debt decreased from US$18,050 million in 2021 to US$12,929 million in 2025. Total shareholders’ investment increased steadily over the same period, rising from US$35,802 million to US$52,130 million. This combined effect of decreasing debt and increasing equity is the primary driver of the observed trend in the debt to equity ratio.
The consistent reduction in the debt to equity ratio suggests improving financial health and a reduced risk profile. The company appears to be strategically managing its capital structure, prioritizing equity financing and reducing its dependence on debt.
Debt to Equity (including Operating Lease Liability)
Abbott Laboratories, debt to equity (including operating lease liability) calculation, comparison to benchmarks
| Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | ||
|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | ||||||
| Current portion of long-term debt | ||||||
| Long-term debt, excluding current portion | ||||||
| Total debt | ||||||
| Operating lease liability, current (included in Other accrued liabilities) | ||||||
| Operating lease liability, non-current | ||||||
| Total debt (including operating lease liability) | ||||||
| Total Abbott shareholders’ investment | ||||||
| Solvency Ratio | ||||||
| Debt to equity (including operating lease liability)1 | ||||||
| Benchmarks | ||||||
| Debt to Equity (including Operating Lease Liability), Competitors2 | ||||||
| Elevance Health Inc. | ||||||
| Intuitive Surgical Inc. | ||||||
| Medtronic PLC | ||||||
| UnitedHealth Group Inc. | ||||||
| Debt to Equity (including Operating Lease Liability), Sector | ||||||
| Health Care Equipment & Services | ||||||
| Debt to Equity (including Operating Lease Liability), Industry | ||||||
| Health Care | ||||||
Based on: 10-K (reporting date: 2025-12-31), 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31).
1 2025 Calculation
Debt to equity (including operating lease liability) = Total debt (including operating lease liability) ÷ Total Abbott shareholders’ investment
= ÷ =
2 Click competitor name to see calculations.
The debt to equity ratio, including operating lease liability, demonstrates a consistent downward trend over the five-year period. Total debt decreased from US$19,251 million in 2021 to US$14,136 million in 2025, while total shareholders’ investment increased from US$35,802 million to US$52,130 million over the same timeframe. This combination resulted in a decreasing ratio, indicating a strengthening solvency position.
- Debt to Equity Ratio Trend
- The ratio declined steadily from 0.54 in 2021 to 0.27 in 2025. The most significant decrease occurred between 2023 and 2024, moving from 0.41 to 0.32. This suggests a more pronounced focus on reducing leverage or a substantial increase in equity during that period.
- Total Debt
- Total debt exhibited a consistent year-over-year decrease throughout the period. The reduction was most substantial between 2021 and 2022, with a decrease of US$1,305 million. Subsequent annual reductions were more moderate, indicating a potentially planned and managed debt repayment strategy.
- Shareholders’ Investment
- Total shareholders’ investment increased each year. The largest absolute increase occurred between 2024 and 2025, with an increase of US$4,466 million. This growth in equity contributed significantly to the declining debt to equity ratio and suggests positive investor confidence or internal capital generation.
The observed trends suggest a decreasing reliance on debt financing and a strengthening financial foundation. The consistent decline in the debt to equity ratio indicates reduced financial risk and improved capacity to meet long-term obligations.
Debt to Capital
| Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | ||
|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | ||||||
| Current portion of long-term debt | ||||||
| Long-term debt, excluding current portion | ||||||
| Total debt | ||||||
| Total Abbott shareholders’ investment | ||||||
| Total capital | ||||||
| Solvency Ratio | ||||||
| Debt to capital1 | ||||||
| Benchmarks | ||||||
| Debt to Capital, Competitors2 | ||||||
| Elevance Health Inc. | ||||||
| Intuitive Surgical Inc. | ||||||
| Medtronic PLC | ||||||
| UnitedHealth Group Inc. | ||||||
| Debt to Capital, Sector | ||||||
| Health Care Equipment & Services | ||||||
| Debt to Capital, Industry | ||||||
| Health Care | ||||||
Based on: 10-K (reporting date: 2025-12-31), 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31).
1 2025 Calculation
Debt to capital = Total debt ÷ Total capital
= ÷ =
2 Click competitor name to see calculations.
The debt to capital ratio demonstrates a consistent downward trend over the five-year period. This indicates a decreasing reliance on debt financing relative to the company’s total capital structure.
- Total Debt
- Total debt decreased from US$18,050 million in 2021 to US$12,929 million in 2025. The largest reduction occurred between 2021 and 2022, followed by a more gradual decline in subsequent years. This suggests active debt management or repayment strategies were employed.
- Total Capital
- Total capital remained relatively stable between 2021 and 2023, fluctuating around US$53.5 billion. A notable increase is observed between 2023 and 2024, reaching US$61,789 million, and continuing to US$65,059 million in 2025. This growth in total capital suggests increased equity or other forms of non-debt financing.
- Debt to Capital Ratio
- The debt to capital ratio declined steadily from 0.34 in 2021 to 0.20 in 2025. This consistent decrease signifies an improvement in the company’s solvency position. A lower ratio generally indicates a reduced risk of financial distress and greater financial flexibility. The rate of decline accelerated between 2023 and 2025, coinciding with the more substantial increase in total capital.
The observed trends suggest the company is actively strengthening its financial position by reducing its debt burden and expanding its capital base. This could be due to increased profitability, strategic asset sales, or successful equity offerings.
Debt to Capital (including Operating Lease Liability)
Abbott Laboratories, debt to capital (including operating lease liability) calculation, comparison to benchmarks
| Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | ||
|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | ||||||
| Current portion of long-term debt | ||||||
| Long-term debt, excluding current portion | ||||||
| Total debt | ||||||
| Operating lease liability, current (included in Other accrued liabilities) | ||||||
| Operating lease liability, non-current | ||||||
| Total debt (including operating lease liability) | ||||||
| Total Abbott shareholders’ investment | ||||||
| Total capital (including operating lease liability) | ||||||
| Solvency Ratio | ||||||
| Debt to capital (including operating lease liability)1 | ||||||
| Benchmarks | ||||||
| Debt to Capital (including Operating Lease Liability), Competitors2 | ||||||
| Elevance Health Inc. | ||||||
| Intuitive Surgical Inc. | ||||||
| Medtronic PLC | ||||||
| UnitedHealth Group Inc. | ||||||
| Debt to Capital (including Operating Lease Liability), Sector | ||||||
| Health Care Equipment & Services | ||||||
| Debt to Capital (including Operating Lease Liability), Industry | ||||||
| Health Care | ||||||
Based on: 10-K (reporting date: 2025-12-31), 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31).
1 2025 Calculation
Debt to capital (including operating lease liability) = Total debt (including operating lease liability) ÷ Total capital (including operating lease liability)
= ÷ =
2 Click competitor name to see calculations.
The debt to capital ratio, inclusive of operating lease liabilities, demonstrates a consistent downward trend over the five-year period. Total debt decreased from US$19,251 million in 2021 to US$14,136 million in 2025. Simultaneously, total capital experienced a more moderate increase, moving from US$55,053 million in 2021 to US$66,266 million in 2025.
- Debt to Capital Ratio Trend
- The ratio declined steadily from 0.35 in 2021 to 0.21 in 2025. This indicates a decreasing reliance on debt financing relative to the company’s total capital structure. The most significant decrease occurred between 2022 and 2023, dropping from 0.33 to 0.29, and again between 2023 and 2024, falling to 0.24. The rate of decline slowed between 2024 and 2025.
The observed reduction in the debt to capital ratio suggests improved financial leverage and a potentially stronger financial position. The increase in total capital, while not as dramatic as the debt reduction, contributes to this improved ratio by expanding the equity base. This trend could be indicative of successful debt repayment strategies, increased profitability leading to retained earnings, or equity issuances.
- Total Debt
- Total debt decreased each year throughout the period. The largest absolute reduction in debt occurred between 2021 and 2022, with a decrease of US$1,305 million. Subsequent annual reductions were smaller, but consistent.
- Total Capital
- Total capital remained relatively stable between 2021 and 2023, fluctuating within a narrow range. A notable increase occurred between 2023 and 2024, rising to US$62,939 million, and continued into 2025, reaching US$66,266 million. This suggests a shift in capital structure towards greater equity or other forms of capital beyond debt.
In summary, the company has demonstrably reduced its debt burden relative to its capital base over the analyzed period. This trend is characterized by consistent declines in the debt to capital ratio, driven by both debt reduction and capital increases, particularly in the later years of the period.
Debt to Assets
| Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | ||
|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | ||||||
| Current portion of long-term debt | ||||||
| Long-term debt, excluding current portion | ||||||
| Total debt | ||||||
| Total assets | ||||||
| Solvency Ratio | ||||||
| Debt to assets1 | ||||||
| Benchmarks | ||||||
| Debt to Assets, Competitors2 | ||||||
| Elevance Health Inc. | ||||||
| Intuitive Surgical Inc. | ||||||
| Medtronic PLC | ||||||
| UnitedHealth Group Inc. | ||||||
| Debt to Assets, Sector | ||||||
| Health Care Equipment & Services | ||||||
| Debt to Assets, Industry | ||||||
| Health Care | ||||||
Based on: 10-K (reporting date: 2025-12-31), 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31).
1 2025 Calculation
Debt to assets = Total debt ÷ Total assets
= ÷ =
2 Click competitor name to see calculations.
The debt-to-assets ratio demonstrates a consistent downward trend over the five-year period. This indicates a decreasing reliance on debt financing relative to the company’s total asset base.
- Debt to Assets Ratio Trend
- In 2021, the debt-to-assets ratio was 0.24. This decreased to 0.23 in 2022, continuing to 0.20 in 2023. The decline accelerated in 2024, reaching 0.17, and further decreased to 0.15 in 2025.
The observed reduction in the debt-to-assets ratio suggests improved solvency. The company is financing a greater proportion of its assets with equity rather than debt. This could be due to debt repayment, increased asset growth, or a combination of both. The acceleration of the decline in recent years indicates a strengthening financial position with respect to leverage.
- Total Debt
- Total debt decreased from US$18,050 million in 2021 to US$12,929 million in 2025. This reduction contributes directly to the declining debt-to-assets ratio.
- Total Assets
- Total assets experienced a moderate decrease from US$75,196 million in 2021 to US$73,214 million in 2023, then increased to US$86,713 million in 2025. The asset growth in the later years, coupled with decreasing debt, further supports the improvement in the debt-to-assets ratio.
The consistent decrease in the debt-to-assets ratio is a positive indicator of financial health. It suggests the company is becoming less risky from a solvency perspective and has greater capacity to absorb potential financial shocks.
Debt to Assets (including Operating Lease Liability)
Abbott Laboratories, debt to assets (including operating lease liability) calculation, comparison to benchmarks
| Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | ||
|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | ||||||
| Current portion of long-term debt | ||||||
| Long-term debt, excluding current portion | ||||||
| Total debt | ||||||
| Operating lease liability, current (included in Other accrued liabilities) | ||||||
| Operating lease liability, non-current | ||||||
| Total debt (including operating lease liability) | ||||||
| Total assets | ||||||
| Solvency Ratio | ||||||
| Debt to assets (including operating lease liability)1 | ||||||
| Benchmarks | ||||||
| Debt to Assets (including Operating Lease Liability), Competitors2 | ||||||
| Elevance Health Inc. | ||||||
| Intuitive Surgical Inc. | ||||||
| Medtronic PLC | ||||||
| UnitedHealth Group Inc. | ||||||
| Debt to Assets (including Operating Lease Liability), Sector | ||||||
| Health Care Equipment & Services | ||||||
| Debt to Assets (including Operating Lease Liability), Industry | ||||||
| Health Care | ||||||
Based on: 10-K (reporting date: 2025-12-31), 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31).
1 2025 Calculation
Debt to assets (including operating lease liability) = Total debt (including operating lease liability) ÷ Total assets
= ÷ =
2 Click competitor name to see calculations.
The Debt to Assets ratio, including operating lease liability, demonstrates a consistent downward trend over the five-year period from 2021 to 2025. This indicates a decreasing reliance on debt financing relative to the company’s asset base.
- Debt to Assets Ratio Trend
- In 2021, the ratio stood at 0.26. It decreased to 0.24 in 2022, and continued to decline to 0.22 in 2023. The rate of decline accelerated in 2024, reaching 0.19, and further decreased to 0.16 in 2025.
Total debt, including operating lease liability, has decreased each year, moving from US$19,251 million in 2021 to US$14,136 million in 2025. This reduction in debt contributes directly to the observed decline in the Debt to Assets ratio.
- Total Debt
- The most significant reduction in total debt occurred between 2022 and 2023, with a decrease of US$1,069 million. While subsequent yearly decreases were smaller in absolute terms, they continued the overall downward trajectory.
Total assets experienced a slight decrease between 2021 and 2023, falling from US$75,196 million to US$73,214 million. However, assets then increased substantially in 2024 and 2025, reaching US$86,713 million. The increase in total assets in the later years, coupled with the continued reduction in debt, further contributed to the declining Debt to Assets ratio.
- Total Assets
- The increase in total assets between 2023 and 2025 (US$13,500 million) was more substantial than the total debt reduction over the same period (US$1,737 million). This suggests that asset growth is outpacing debt reduction, reinforcing the improving solvency position.
The consistent decrease in the Debt to Assets ratio suggests improving financial leverage and a stronger solvency position over the analyzed period.
Financial Leverage
| Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | ||
|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | ||||||
| Total assets | ||||||
| Total Abbott shareholders’ investment | ||||||
| Solvency Ratio | ||||||
| Financial leverage1 | ||||||
| Benchmarks | ||||||
| Financial Leverage, Competitors2 | ||||||
| Elevance Health Inc. | ||||||
| Intuitive Surgical Inc. | ||||||
| Medtronic PLC | ||||||
| UnitedHealth Group Inc. | ||||||
| Financial Leverage, Sector | ||||||
| Health Care Equipment & Services | ||||||
| Financial Leverage, Industry | ||||||
| Health Care | ||||||
Based on: 10-K (reporting date: 2025-12-31), 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31).
1 2025 Calculation
Financial leverage = Total assets ÷ Total Abbott shareholders’ investment
= ÷ =
2 Click competitor name to see calculations.
The financial leverage of the company, as indicated by the provided figures, demonstrates a consistent downward trend over the five-year period from 2021 to 2025. Simultaneously, total assets experienced fluctuations, while total shareholders’ investment increased steadily.
- Financial Leverage
- The financial leverage ratio decreased from 2.10 in 2021 to 1.66 in 2025. This indicates a diminishing reliance on debt financing relative to equity. The decline was most pronounced between 2021 and 2023, decreasing from 2.10 to 1.90, and then continued at a slower pace through 2025. This suggests a deliberate strategy to reduce financial risk or an increased capacity to fund operations through equity.
- Total Assets
- Total assets decreased from US$75,196 million in 2021 to US$73,214 million in 2023, representing a contraction in the company’s asset base. However, assets then increased significantly to US$81,414 million in 2024 and further to US$86,713 million in 2025. This rebound suggests potential acquisitions, significant capital investments, or positive revaluation of existing assets.
- Total Shareholders’ Investment
- Total shareholders’ investment exhibited a consistent upward trend throughout the period, increasing from US$35,802 million in 2021 to US$52,130 million in 2025. This growth could be attributed to retained earnings, new equity issuances, or an increase in stock value. The consistent increase in equity supports the observed decrease in financial leverage, indicating a strengthening of the company’s financial position.
The combination of decreasing financial leverage and increasing shareholders’ investment suggests a strengthening capital structure. The asset fluctuations, particularly the recovery in 2024 and 2025, warrant further investigation to understand the drivers behind the changes in the company’s asset base.
Interest Coverage
| Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | ||
|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | ||||||
| Net earnings | ||||||
| Add: Income tax expense | ||||||
| Add: Interest expense | ||||||
| Earnings before interest and tax (EBIT) | ||||||
| Solvency Ratio | ||||||
| Interest coverage1 | ||||||
| Benchmarks | ||||||
| Interest Coverage, Competitors2 | ||||||
| Elevance Health Inc. | ||||||
| Intuitive Surgical Inc. | ||||||
| Medtronic PLC | ||||||
| UnitedHealth Group Inc. | ||||||
| Interest Coverage, Sector | ||||||
| Health Care Equipment & Services | ||||||
| Interest Coverage, Industry | ||||||
| Health Care | ||||||
Based on: 10-K (reporting date: 2025-12-31), 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31).
1 2025 Calculation
Interest coverage = EBIT ÷ Interest expense
= ÷ =
2 Click competitor name to see calculations.
The interest coverage ratio exhibited fluctuations over the five-year period. Initial values were strong, followed by a decline, and then a recovery towards the end of the analyzed timeframe. Earnings before interest and tax (EBIT) and interest expense both influenced these changes.
- Overall Trend
- The interest coverage ratio began at 16.41 in 2021, decreased to a low of 11.46 in 2023, and then increased to 18.17 by 2025. This indicates a period of reduced ability to cover interest obligations, followed by a strengthening of that ability.
- EBIT Influence
- EBIT demonstrated an initial increase from US$8,744 million in 2021 to US$8,864 million in 2022. A subsequent decrease to US$7,301 million in 2023 contributed to the lowest interest coverage ratio during the period. EBIT then recovered, reaching US$8,959 million in 2025, supporting the improvement in the interest coverage ratio.
- Interest Expense Influence
- Interest expense increased from US$533 million in 2021 to US$558 million in 2022, and further to US$637 million in 2023. This rise in interest expense, coupled with the decline in EBIT, significantly lowered the interest coverage ratio in 2023. Interest expense decreased to US$559 million in 2024 and US$493 million in 2025, contributing to the ratio’s subsequent improvement.
The combination of EBIT and interest expense movements suggests that the company’s capacity to meet its interest obligations is sensitive to changes in both operating profitability and financing costs. The recovery in both EBIT and the reduction in interest expense in the later years of the period resulted in a substantially improved interest coverage position.
Fixed Charge Coverage
| Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | ||
|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | ||||||
| Net earnings | ||||||
| Add: Income tax expense | ||||||
| Add: Interest expense | ||||||
| Earnings before interest and tax (EBIT) | ||||||
| Add: Operating lease cost | ||||||
| Earnings before fixed charges and tax | ||||||
| Interest expense | ||||||
| Operating lease cost | ||||||
| Fixed charges | ||||||
| Solvency Ratio | ||||||
| Fixed charge coverage1 | ||||||
| Benchmarks | ||||||
| Fixed Charge Coverage, Competitors2 | ||||||
| Elevance Health Inc. | ||||||
| Intuitive Surgical Inc. | ||||||
| Medtronic PLC | ||||||
| UnitedHealth Group Inc. | ||||||
| Fixed Charge Coverage, Sector | ||||||
| Health Care Equipment & Services | ||||||
| Fixed Charge Coverage, Industry | ||||||
| Health Care | ||||||
Based on: 10-K (reporting date: 2025-12-31), 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31).
1 2025 Calculation
Fixed charge coverage = Earnings before fixed charges and tax ÷ Fixed charges
= ÷ =
2 Click competitor name to see calculations.
The company’s fixed charge coverage exhibited fluctuations over the five-year period. Earnings before fixed charges and tax, the numerator in the calculation, demonstrated an initial increase followed by a decline and subsequent recovery. Fixed charges, representing the company’s obligations requiring periodic payments, generally increased before decreasing in the later years.
- Fixed Charge Coverage Trend
- The fixed charge coverage ratio began at 10.21 in 2021 and decreased to 7.71 in 2023. This represents a substantial decline in the company’s ability to cover its fixed charges with earnings. A subsequent increase to 8.58 in 2024 and further to 10.58 in 2025 indicates a recovery and strengthening of this coverage.
- Earnings Before Fixed Charges and Tax
- Earnings before fixed charges and tax increased from US$9,103 million in 2021 to US$9,219 million in 2022, suggesting improved operational performance. However, a decrease to US$7,657 million in 2023 indicates a weakening of earnings. The subsequent rise to US$7,938 million in 2024 and a more significant increase to US$9,350 million in 2025 demonstrates a recovery and surpassing of the initial 2021 level.
- Fixed Charges
- Fixed charges increased from US$892 million in 2021 to US$993 million in 2023, reflecting growing financial obligations. A decrease to US$925 million in 2024 and a further reduction to US$884 million in 2025 suggests a reduction in these obligations, potentially through debt repayment or refinancing.
The interplay between earnings and fixed charges significantly impacted the fixed charge coverage ratio. The decline in earnings in 2023, coupled with increasing fixed charges, led to the lowest coverage ratio during the period. The subsequent recovery in earnings and decrease in fixed charges contributed to the improved coverage observed in 2024 and 2025.